Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout
In Vivo · 2025
DOI: 10.21873/invivo.13915 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Sung Soo Ahn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Kore…. Hauptthemen laut MEDLINE: Gout, HLA-B Antigens. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Allopurinol is a standard agent used for lowering uric acid levels. Human leukocyte antigen (HLA)-B5801 positivity increases the incidence of severe cutaneous adverse reactions (SCARs) in allopurinol users. HLA alleles HLA-B27 and HLA-B51 are frequently found in patients with ankylosing spondylitis and Behçet's disease, showing an association with distinct clinical features. In this study, we investigated the association between the HLA-B5801 genotype and patient characteristics and outcomes in gout. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 263 patients with gout who were not receiving uric acid-lowering therapy and were tested for HLA-B5801 positivity between March 2020 and February 2024. Patients were classified according to their HLA-B5801 status, and patient demographics and laboratory variables were compared. The incidence of gout flares or severe flares requiring hospital care within one year was investigated. RESULTS: A total of 37 participants were HLA-B5801 positive (37/263, 14.1%). However, no significant differences were observed in demographic or laboratory variables between the HLA-B5801 positive and negative groups. Subgroup analyses of patients with new-onset gout, males, and those with an estimated glomerular filtration rate ≥60 ml/min/1.73 m2 also demonstrated no significant differences related to HLA-B5801 genotype positivity. The incidence of disease flares or severe flares between patients in the HLA-B5801 positive and negative groups was comparable during the one-year follow-up. CONCLUSION: Although HLA-B5801 was a significant predictor of allopurinol-associated SCARs, the impact of HLA-B5801 positivity on the clinical characteristics or flares was not evident in this population of patients with gout.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
- Department of Emergency Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Orthopaedic Surgery, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea bae_k_h@naver.com.
Zitieren
APA
Ahn, S. S., Kim, J. A., & Bae, K. (2025). Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout. In Vivo. https://doi.org/10.21873/invivo.13915
Vancouver
Ahn SS, Kim JA, Bae K. Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout. In Vivo. 2025. doi:10.21873/invivo.13915
BibTeX
@article{Ahn2025,
author = {Ahn, Sung Soo and Kim, Jiyoung Agatha and Bae, Kunhyung},
title = {Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13915}
}
EUVIMED